Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA1094973
Max Phase: Preclinical
Molecular Formula: C11H18N5O14P3
Molecular Weight: 537.21
Molecule Type: Small molecule
Associated Items:
ID: ALA1094973
Max Phase: Preclinical
Molecular Formula: C11H18N5O14P3
Molecular Weight: 537.21
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: C[n+]1cn([C@@H]2O[C@H](COP(=O)([O-])OP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]2O)c2nc(N)[nH]c(=O)c21
Standard InChI: InChI=1S/C11H18N5O14P3/c1-15-3-16(8-5(15)9(19)14-11(12)13-8)10-7(18)6(17)4(28-10)2-27-32(23,24)30-33(25,26)29-31(20,21)22/h3-4,6-7,10,17-18H,2H2,1H3,(H6-,12,13,14,19,20,21,22,23,24,25,26)/t4-,6-,7-,10-/m1/s1
Standard InChI Key: DKVRNHPCAOHRSI-KQYNXXCUSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 537.21 | Molecular Weight (Monoisotopic): 537.0063 | AlogP: -3.54 | #Rotatable Bonds: 8 |
Polar Surface Area: 292.92 | Molecular Species: ACID | HBA: 14 | HBD: 7 |
#RO5 Violations: 3 | HBA (Lipinski): 19 | HBD (Lipinski): 8 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 0.90 | CX Basic pKa: 0.22 | CX LogP: -8.10 | CX LogD: -13.91 |
Aromatic Rings: 2 | Heavy Atoms: 33 | QED Weighted: 0.13 | Np Likeness Score: 1.20 |
1. Kowalska J, Lukaszewicz M, Zuberek J, Ziemniak M, Darzynkiewicz E, Jemielity J.. (2009) Phosphorothioate analogs of m7GTP are enzymatically stable inhibitors of cap-dependent translation., 19 (7): [PMID:19269171] [10.1016/j.bmcl.2009.02.053] |
2. Jia Y, Chiu TL, Amin EA, Polunovsky V, Bitterman PB, Wagner CR.. (2010) Design, synthesis and evaluation of analogs of initiation factor 4E (eIF4E) cap-binding antagonist Bn7-GMP., 45 (4): [PMID:20060622] [10.1016/j.ejmech.2009.11.054] |
3. Chen X, Kopecky DJ, Mihalic J, Jeffries S, Min X, Heath J, Deignan J, Lai S, Fu Z, Guimaraes C, Shen S, Li S, Johnstone S, Thibault S, Xu H, Cardozo M, Shen W, Walker N, Kayser F, Wang Z.. (2012) Structure-guided design, synthesis, and evaluation of guanine-derived inhibitors of the eIF4E mRNA-cap interaction., 55 (8): [PMID:22458568] [10.1021/jm300037x] |
4. Piecyk K, Davis RE, Jankowska-Anyszka M.. (2012) Synthesis of N²-modified 7-methylguanosine 5'-monophosphates as nematode translation inhibitors., 20 (15): [PMID:22748379] [10.1016/j.bmc.2012.05.078] |
5. Ziemniak M, Kowalska J, Lukaszewicz M, Zuberek J, Wnek K, Darzynkiewicz E, Jemielity J.. (2015) Phosphate-modified analogues of m(7)GTP and m(7)Gppppm(7)G-Synthesis and biochemical properties., 23 (17): [PMID:26264844] [10.1016/j.bmc.2015.07.052] |
Source(1):